NCT03580200 is a NA clinical trial of Trigger Point Dry Needling in Trigger Point, sponsored by Emily Slaven, PT, PhD.

Who is sponsoring NCT03580200?

NCT03580200 is sponsored by Emily Slaven, PT, PhD.

What drugs are being tested in NCT03580200?

Interventions in NCT03580200: Trigger Point Dry Needling.

What condition does NCT03580200 study?

NCT03580200 studies Trigger Point, Muscle Weakness.

Is NCT03580200 still recruiting?

NCT03580200 is currently completed. Last updated 26 September 2019.

Last reviewed 2019-09-26 · How we verify

NCT03580200

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Deep Trigger Point Dry Needling on Strength Measurements of the Gluteus Medius Musculature

Completed NA Last updated 26 September 2019

What this trial tests

NA trial testing Trigger Point Dry Needling in Trigger Point in 40 participants. Completed in 31 May 2019.

Timeline

17 December 2018

Primary endpoint
31 May 2019

31 May 2019

Quick facts

Lead sponsor	Emily Slaven, PT, PhD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	17 December 2018
Primary completion	31 May 2019
Estimated completion	31 May 2019
Sites	1 location across United States

Drugs / interventions tested

Trigger Point Dry Needling

Conditions studied

Trigger Point — all drugs for Trigger Point →
Muscle Weakness — all drugs for Muscle Weakness →

Sponsor

Emily Slaven, PT, PhD

Who can join

Adults 18 to 50, any sex, with Trigger Point or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study will be to assess the effect that the application of deep trigger point dry needling to latent trigger points has on strength measurements. Specifically, the effect of deep trigger point dry needling on the strength measurements of the gluteus medius musculature immediately following intervention will be investigated. The author hypothesizes that there will be a significant difference in strength measurements of the gluteus medius musculature between the intervention and controls sides as well as within the intervention and control sides prior to and immediately following the application of deep trigger point dry needling. It is the authors' intention that clinicians may be able to apply the results of this study to generate a safe and effective treatment plan that can reduce the risk for trunk and lower extremity injuries within their patient population by reducing the number of latent trigger points within muscle tissue.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Trigger Point Dry Needling on Strength Measurements and Activation Levels of the Gluteus Medius: A Quasi-Experimental Randomized Control Study.
Schneider E, Moore ES, Stanborough R, Slaven E. · · 2022 · cited 7× · PMID 36518833 · DOI 10.26603/001c.55536

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03580200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emily Slaven, PT, PhD
Last refreshed: 26 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03580200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing